SunTrust Robinson Humphrey Initiates Coverage On Momenta Pharmaceuticals with Buy Rating, Announces $29 Price Target

SunTrust Robinson Humphrey initiates coverage on Momenta Pharmaceuticals (NASDAQ:MNTA) with a Buy rating and a $29 price target.

Benzinga · 11/12/2019 11:30

SunTrust Robinson Humphrey initiates coverage on Momenta Pharmaceuticals (NASDAQ:MNTA) with a Buy rating and a $29 price target.